Roche's Herceptin sensitivity test wins FDA nod

The FDA has approved a genetic test made by Roche's Ventana Medical Systems unit that more easily identifies ideal candidates for its breast cancer treatment Herceptin. Report

Suggested Articles

An oncologist leader RBC Capital Markets interviewed expressed comfort that Trodelvy will succeed in earlier-line TNBC and in HR-positive disease.

Gilead Sciences is the latest drugmaker to settle Justice Department claims that its charity contributions were actually kickbacks.

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.